Candidate gene
| MAGEC2/CT-10 may be a good candidate for peptide vaccination in patients with hepatocellular carcinoma |
Marker
| expression of MAGEC1/CT7 and MAGEC2/CT10 in osteolytic lesions of myeloma patients can be used for diagnostic, prognostic, as well as immunotherapeutic purposes |
Therapy target
|
System | Type | Disorder | Pubmed |
cancer | hemopathy | | |
MAGEC2-specific immunotherapies have the potential to eradicate the most malignant cells within the myeloma tumour bulk leading to durable clinical responses | cancer | reproductive | breast | |
targeting MAGEC2 may provide a novel therapeutic strategy for breast cancer treatment | cancer | reproductive | prostate | |
potential target for adjuvant and palliative immunotherapy in patients with prostate cancer |
| |